Arcutis Biotherapeutics, Inc.

Direct answer

Arcutis Biotherapeutics, Inc. is publicly traded on NASDAQ under the ticker ARQT.

Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes...

Can you invest in Arcutis Biotherapeutics, Inc.?

Yes. Arcutis Biotherapeutics, Inc. trades publicly on NASDAQ as ARQT.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for Arcutis Biotherapeutics, Inc.

Detailed equity research is provided by MarketSnap.